Going-concern and financing risk
The company reports limited operations and no revenue, and has relied on related-party loans.
- Scope
- Corporate liquidity and continuity
- Materiality
- high
Nika Pharmaceuticals, Inc
Nika Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company focused on developing, licensing, and commercializing medicinal products and dietary supplements through a network of agreements and subsidiaries. Its portfolio includes patented and licensed pharmaceutical technologies, generic tablet products, injectable drug manufacturing capabilities, and nutraceutical products with international distribution rights.
0.07
0.07
| % | |
|---|---|
| Licensed pharmaceuticals | 35% Medicinal products and technologies licensed for registration, production, and sale. |
| Dietary supplements | 20% Supplement products marketed under exclusive rights agreements in multiple regions. |
| Generic drug technologies | 20% Tablet-form generic drug technologies acquired for development and commercialization. |
| Manufacturing infrastructure | 15% Pharmaceutical production assets and equipment used to support future drug output. |
| Licensing and distribution rights | 10% Exclusive rights and joint business arrangements covering product commercialization. |
The company’s customers are primarily pharmaceutical distributors, healthcare market participants, and commercial...
- Pharmaceutical distributorsprimary
Buy medicinal products and generic drugs for regional resale and market access.
- Licensing and commercialization partnersprimary
Work with the company on registration, production, and distribution of licensed products.
- Dietary supplement buyerssecondary
Purchase supplement products such as Hypocholestin and Silymaron through retail or channel partners.
- Healthcare and clinical channelssecondary
Potential buyers or users of medicinal products such as TNG-based therapies.
- Manufacturing counterpartiessecondary
Provide equipment, technology, or production services needed to support output.
Nika is organized around U.S. corporate ownership but its commercial footprint is international, with rights and...
- •U.S. parent company with international commercialization rights
- •Europe is a key operating region through Nika Europe Ltd.
- •Bulgarian facilities support manufacturing and production build-out
- •Rights extend across Asia, Africa, the Americas, and Australia
- •Territory coverage affects registration, distribution, and market access
The company’s strategy is to build a commercial pharmaceutical platform around licensed technologies, exclusive product...
01
Commercialize licensed and acquired product technologiesshort-term
The business depends on turning IP rights into marketable products.
02
Build manufacturing and production infrastructuremedium-term
Internal or controlled production capacity supports supply reliability and scale.
03
Expand territorial reachmedium-term
Broader rights increase the addressable market for products and licenses.
04
Use subsidiaries to support operating executionmedium-term
Local entities can help with production, ownership, and market access.
The company faces execution risk because its business model depends on obtaining approvals, building manufacturing...
Regulatory approval and product registration risk
Medicinal products must be registered before production and distribution can scale.
- Scope
- Drug and supplement commercialization
- Materiality
- high
Execution risk on manufacturing build-out
The business depends on completing facilities and equipment installation on schedule.
- Scope
- Factory and vial line deployment
- Materiality
- high
Intellectual property and licensing risk
Value depends on enforceable rights to IPF, TNG, and acquired technologies.
- Scope
- Licensed products and territorial rights
- Materiality
- high
Related-party dependence
Funding and asset transactions have involved officers, directors, and related parties.
- Scope
- Financing and governance
- Materiality
- medium
Going-concern assessment
Affects financial statement presentation and investor assessment of survival risk
Related-party financing
Affects liabilities, cash flow presentation, and governance transparency
Valuation of acquired technologies and rights
Affects intangible assets and future amortization or impairment charges
Asset contributions and acquisitions
Affects balance sheet values and ownership accounting
: 29.4.2026